In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
NovoCure Ltd (NASDAQ: NVCR) closed the day trading at $18.19 down -1.19% from the previous closing price of $18.41. In other words, the price has decreased by -$1.19 from its previous closing price. On the day, 1.3 million shares were traded.
Ratios:
For a better understanding of NVCR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.46. In the meantime, Its Debt-to-Equity ratio is 1.90 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on December 02, 2024, Upgraded its rating to Outperform and sets its target price to $30 from $18 previously.
On October 16, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $24 to $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when Weinberg Uri sold 268 shares for $18.92 per share. The transaction valued at 5,071 led to the insider holds 166,243 shares of the business.
Leonard Frank X sold 2,527 shares of NVCR for $46,841 on Mar 03 ’25. The EVP, Pres., Novocure Oncology now owns 143,673 shares after completing the transaction at $18.54 per share. On Mar 03 ’25, another insider, Cordova Ashley, who serves as the Chief Executive Officer of the company, sold 2,053 shares for $18.54 each. As a result, the insider received 38,055 and left with 204,005 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.30 while its Price-to-Book (P/B) ratio in mrq is 5.48.
Stock Price History:
Over the past 52 weeks, NVCR has reached a high of $34.13, while it has fallen to a 52-week low of $11.70. The 50-Day Moving Average of the stock is -28.36%, while the 200-Day Moving Average is calculated to be -12.65%.
Shares Statistics:
A total of 108.52M shares are outstanding, with a floating share count of 98.84M. Insiders hold about 10.08% of the company’s shares, while institutions hold 83.65% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 6.0 analysts. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.43 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$1.7 and -$2.79 for the fiscal current year, implying an average EPS of -$2.05. EPS for the following year is -$2.01, with 7.0 analysts recommending between -$1.48 and -$2.59.
Revenue Estimates
6 analysts predict $147.24M in revenue for the current quarter. It ranges from a high estimate of $150.3M to a low estimate of $143M. As of the current estimate, NovoCure Ltd’s year-ago sales were $138.5MFor the next quarter, 6 analysts are estimating revenue of $150.6M. There is a high estimate of $152.1M for the next quarter, whereas the lowest estimate is $148M.
A total of 6 analysts have provided revenue estimates for NVCR’s current fiscal year. The highest revenue estimate was $619M, while the lowest revenue estimate was $608M, resulting in an average revenue estimate of $613.71M. In the same quarter a year ago, actual revenue was $605.22MBased on 8 analysts’ estimates, the company’s revenue will be $678.45M in the next fiscal year. The high estimate is $702M and the low estimate is $649M.
